Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811309 | 1.00 | ESR2 (0.41) | ESR2CYP1A2CCNB2CDK1CCNB1 | |
| SCHEMBL30426382 | 0.86 | ESR2 (0.41) | ESR2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2383512 | 0.86 | ESR2 (0.41) | ESR2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL29811263 | 0.81 | KDM4E (0.45) | MCL1MAPTALDH1A1RAB9ATSHR | |
| SCHEMBL5525919 | 0.81 | KDM4E (0.45) | MCL1MAPTALDH1A1RAB9ATSHR | |
| SCHEMBL29811388 | 0.79 | ATM (0.45) | SRCALDH1A1TP53SMN1; SMN2HPGD | |
| SCHEMBL607256 | 0.79 | PKM (0.44) | JAK2BTKMAPTALDH1A1TSHR | |
| SCHEMBL22239410 | 0.79 | PDE2A (0.46) | ESR2ESR1EGFRSRCALDH1A1 | |
| SCHEMBL29811590 | 0.79 | ALDH1A1 (0.37) | GSK3BCASP3ALDH1A1TSHRHPGD | |
| SCHEMBL4822294 | 0.79 | ATM (0.45) | SRCALDH1A1TP53SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140949-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2024-05-02 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| CN-111825656-B | Inhibitors of protein arginine methyltransferase 5 (PRMT 5), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| WO-2022177305-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | 서울대학교 산학협력단 | 2022-08-25 | — | — | WO | disclosed |
| EP-3190104-B1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007070359-A2 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-3947408-A | ANTIANXIETY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | ESR2 1362/4885CYP1A2 250/4885CCNB2 2186/4885 |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | ESR2 1121/4885CYP1A2 407/4885CCNB2 2440/4885 |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | ESR2 2912/4885CYP1A2 2696/4885CCNB2 1337/4885 |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | ESR2 3045/4885CYP1A2 2446/4885CCNB2 1552/4885 |
| US-11591326-B2 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof | PRMT5, PRMT1, PRMT3 | ESR2 3160/4885CYP1A2 3626/4885CCNB2 2367/4885 |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | EGLN3, HIF1AN, EGLN2 | ESR2 1121/4885CYP1A2 407/4885CCNB2 2440/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | ESR2 2912/4885CYP1A2 2696/4885CCNB2 1337/4885 |
| US-20240140949-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID | HSPH1, HSP90AB2P, HSPBP1 | ESR2 4399/4885CYP1A2 3432/4885CCNB2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.